Abstract
Pulse Biosciences is scheduled to report quarterly results on August 6, 2026 Post Market, and investors will look for clarity on revenue trajectory, margin stabilization, and spending tied to its cardiac ablation program.
Market Forecast
The market expects Pulse Biosciences to post revenue of 0.53 million US dollars this quarter, essentially flat year over year at 0%, with estimated EPS of -$0.36 reflecting a 38.46% YoY decline and EBIT of -$23.32 million implying a 22.75% YoY deterioration. No formal guidance is available for gross profit margin or net profit margin this quarter.
The main business is concentrated in Products, where management’s near-term focus is to support incremental revenue while navigating cost-of-goods and yield dynamics that shaped recent gross margin variability. The most promising program is the nPulse Cardiac Catheter Ablation System, which is advancing through pivotal clinical work; last quarter’s reported revenue was booked under Products at 0.40 million US dollars, flat YoY at 0%, and no separate revenue figure was disclosed for the catheter program.
Last Quarter Review
Pulse Biosciences reported revenue of 0.40 million US dollars, gross profit margin of 7.73%, GAAP net loss attributable to shareholders of 18.58 million US dollars, net profit margin was not disclosed, and adjusted EPS of -$0.24, with revenue, EBIT, and EPS all recorded at 0% year-over-year change per the dataset.
A notable financial development after the quarter was the company’s June 10, 2026 announcement to redeem remaining warrants from the July 2024 rights offering, which could add up to 2.10 million US dollars in gross proceeds if fully exercised and simplifies the capital structure by removing unexercised warrants after the deadline.
In terms of business mix, Products contributed all reported revenue at 0.40 million US dollars, flat YoY at 0%, while the company continued to invest in its catheter ablation platform that does not yet have standalone revenue disclosure; the quarter-on-quarter movement in net profit implied the net loss widened by 6.59%.
Current Quarter Outlook
Main business: Products revenue and gross margin path
The Products line remains the only revenue-reporting category and is expected to deliver around 0.53 million US dollars this quarter based on market forecasts, essentially unchanged year over year. The last reported gross margin of 7.73% underscores how early-stage volume, manufacturing scale, and mix effects can pressure unit economics; management’s operational emphasis this quarter is likely to be on stabilizing costs, improving yields, and tightening procurement to support a path to better margins as volumes normalize. While the forecast set does not include a formal gross margin outlook, the interplay between modest revenue and fixed manufacturing overhead suggests near-term gross margin could remain volatile, and incremental throughput may be the quickest lever for improvement.
Spending on commercialization and product support will shape operating expense intensity and, therefore, earnings per share. The forecast EPS of -$0.36 implies a larger loss year over year, aligning with the EBIT estimate of -$23.32 million and signaling that operating expense growth is expected to outpace the small revenue base. As a result, the key watch items in the print are the realized revenue versus the 0.53 million US dollars expectation, gross profit progression relative to the 7.73% benchmark, and commentary on unit cost trajectories and supply chain readiness for future scale-up.
Most promising business: Cardiac catheter ablation program and execution milestones
The nPulse Cardiac Catheter Ablation System is the company’s most closely watched program, with a pivotal IDE underway for atrial fibrillation. Execution and governance have been reinforced in 2026, including the appointment of a new chief operating officer on April 9, 2026 to oversee clinical, regulatory, quality, and commercial readiness, and the expansion of the chief medical officer role to full time as clinical strategy advances. These moves signal preparation for downstream regulatory and commercial phases even if the near-term revenue base remains confined to Products.
For this quarter’s results, the catheter program is more likely to influence sentiment than revenue, as the market will parse qualitative updates for trial enrollment progress, procedural performance consistency, and any interim learnings that could inform regulatory timelines. Given the revenue estimate is flat YoY and no separate catheter revenue is disclosed, investors will focus on the expense profile tied to the pivotal study, as this is the main driver behind the forecast deterioration in EPS and EBIT YoY. Specific milestones—such as completed enrollments, site activations, or regulatory interactions—could shape the stock’s reaction more than the small revenue base, and management’s guidance on near-term study cadence will be a focal point in the call.
Key stock-price drivers this quarter: Loss trajectory, capital structure actions, and guidance tone
The earnings power narrative this quarter will revolve around how the net loss trajectory compares with the market’s expectations, especially given the dataset’s quarter-on-quarter indicator that the net loss widened by 6.59% in the last period. The forecast for EPS at -$0.36 and EBIT at -$23.32 million sets a low base for profitability, making cost discipline and cash utilization rate central to investor confidence. Any incremental disclosure on operating runway, spend phasing for the pivotal trial, and contingency plans for manufacturing and clinical costs could meaningfully influence the post-print reaction.
Capital structure developments also matter. The June 10, 2026 early redemption of remaining July 2024 rights-offering warrants, triggered by the share-price performance threshold, is a constructive step toward reducing future overhang and tidying the equity stack. If the company confirms incremental gross proceeds near 2.10 million US dollars and clarifies the residual dilution impact from exercised warrants, it would help investors refine their per-share loss trajectory for the rest of the year.
Lastly, the guidance tone—formal or informal—around revenue cadence in Products and the pace of clinical spending will likely outweigh the headline revenue figure in importance. With revenue expected at 0.53 million US dollars and no margin guidance provided, a credible narrative on operational milestones and expense discipline could temper concerns about the projected YoY EPS decline of 38.46%. Management’s commentary on how organizational changes—particularly in clinical and regulatory leadership—are translating into execution efficiency will be closely watched.
Analyst Opinions
Bullish views dominate recent commentary, with a 100% bullish-to-bearish ratio among the opinions collected during the period, reflecting an alignment around program potential and improving capital structure visibility. Oppenheimer maintained an Outperform rating and raised its price target to $35 on July 28, 2026, citing confidence in the company’s program trajectory and forthcoming milestones. Canaccord Genuity initiated coverage at Buy with a $32 price target on June 4, 2026, highlighting the potential for the catheter ablation platform to create value through clinical progress and subsequent commercialization. Mizuho reiterated a Buy rating earlier in the year with a $30 target, reinforcing the constructive stance on development progress and the balance of risk and potential reward.
Across these bullish assessments, three themes recur. The first is that the near-term revenue base is small, but investors should concentrate on the execution cadence of the pivotal study and the company’s ability to convert clinical milestones into future economic value. The second is that recent corporate actions—warrant redemption and leadership appointments—improve visibility on both capital planning and operating execution, which is important when losses are expected to widen in the near term. The third is that even incremental clarity on timelines and cost discipline can serve as catalysts, because expectations for this quarter’s financials are modest, making guidance and qualitative updates the primary drivers of sentiment.
From an expectations-management perspective, the analyst majority is preparing for a quarter where headline numbers underscore early-stage economics—0.53 million US dollars in revenue and a -$0.36 EPS estimate—while the stock’s reaction hinges on qualitative disclosures about study progress, operating spend, and post-quarter updates. If management articulates credible pathways to improve gross margin from the last reported 7.73% and shows concrete momentum in the pivotal IDE, the bullish case envisions the shares reacting positively to color rather than print-outperformance per se. Conversely, a lack of clarity on expense phasing or any slippage in the clinical timeline would be the primary risk to the prevailing positive stance.
Overall, the majority of institutional perspectives remain optimistic, predicated on evidence of disciplined execution and strategic capital measures supporting the pivotal catheter ablation program. This quarter’s preview is less about beating a small revenue number and more about validating the operational thesis that underpins those raised and reiterated targets in the low-to-mid 30s. As such, investors should expect the management’s qualitative commentary—on clinical cadence, cost control, and product readiness—to be the central determinant of whether the quarter is viewed as moving the story forward along the bullish roadmap.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments